Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing…
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing…
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically…
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically…
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003…
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003…
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V….
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V….
Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists ATLANTA, April 03, 2023 (GLOBE…
Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists ATLANTA, April 03, 2023 (GLOBE…
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a…
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a…
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the…
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the…
REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”),…
REDWOOD CITY, Calif., April 03, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”),…
Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit…
Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit…